Condition: Breast Cancer · Sentinel Lymph Node Biopsy (SLNB) · Sentinel Lymph Node Detection · Sponsor: Isabelle Henskens
This pilot study evaluates the diagnostic value of indocyanine green (ICG) fluorescence for sentinel lymph node biopsy (SLNB) performed through the mastectomy incision in breast cancer patients. Women with clinically node-negative, invasive T1-T3 breast cancer undergoing mastectomy with SLNB at St. Antonius or Isala Hospital will be included. All patients receive standard 99mTc injection preoperatively, followed by 5 mg (2mL) ICG injection after anesthesia. The axilla will be explored for fluorescent lymph nodes via the mastectomy incision, avoiding a separate axillary incision. Primary outcome: ICG detection rate for SLN identification via the mastectomy incision. Secondary outcomes: Comparison with 99mTc detection, number of nodes identified, concordance between methods, pathology differences, detection time, and complications. ICG is safe, non-ionizing, and causes no extra discomfort or visits. Risks and burden are minimal.
This description comes directly from the study's public registry record.
Isabelle Henskens, MD · +31883202902 · i.henskens@antoniusziekenhuis.nl
Annemiek Doeksen, MD, PhD · +3183202900 · a.doeksen@antoniusziekenhuis.nl
Always discuss trial participation with your own doctor first.
| Isala | Zwolle, Overijssel, Netherlands | Recruiting |
| St. Antonius Ziekenhuis | Utrecht, Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07362485